Development of Streptococcus pneumoniae Vaccines Using Live Vectors
Related Experiment Video
Updated: Jan 18, 2026
Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
1Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
Insights
Developing novel protein-based vaccines against Streptococcus pneumoniae is crucial. Live recombinant vaccines using attenuated bacteria show promise for universal protection, overcoming limitations of current options.
Area of Science:
- Microbiology
- Vaccinology
- Immunology
Background:
- Streptococcus pneumoniae causes significant global morbidity and mortality, particularly in vulnerable populations.
- Current capsular vaccines face challenges like serotype replacement, limited coverage, and high costs.
- Protein-based universal vaccines are being developed to address these limitations.
Purpose of the Study:
- To review research on live recombinant vaccines for Streptococcus pneumoniae.
- To explore the use of live attenuated Salmonella and lactic acid bacteria as vectors for pneumococcal antigens.
- To discuss the limitations and future prospects of these novel vaccine strategies.
Main Methods:
- Review of scientific literature on live recombinant vaccines.
- Focus on attenuated Salmonella and lactic acid bacteria as delivery vectors.
- Analysis of studies delivering pneumococcal antigens via these vectors.
Main Results:
- Live recombinant vaccines utilizing attenuated bacteria are a promising approach.
- These vaccines aim to deliver protective pneumococcal antigens.
- Research highlights potential but also identifies limitations.
Conclusions:
- Live attenuated bacterial vectors offer a promising platform for universal Streptococcus pneumoniae vaccines.
- Further research is needed to overcome current limitations and optimize efficacy.
- These novel vaccines hold potential to improve global health outcomes against pneumococcal disease.
Abstract:
Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines.
